Board Member
Faeth Therapeutics, Inc. (FTH)Chief Accounting Officer
4D Molecular Therapeutics, Inc. (FDMT)Chief Accounting Officer
Viridian Therapeutics, Inc.\DE (VRDN)Equibles does not estimate personal net worth.
Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FDMT alertsKristian Humer is recorded as Chief Accounting Officer at 4D Molecular Therapeutics, Inc. (FDMT) since March 25, 2026, CFO at 4D Molecular Therapeutics, Inc. (FDMT), Board Member at Faeth Therapeutics, Inc. (FTH) since June 10, 2026 and Chief Accounting Officer at Viridian Therapeutics, Inc.\DE (VRDN) since July 26, 2021. The newest filing on record that lists Kristian Humer as CFO at 4D Molecular Therapeutics, Inc. (FDMT) is dated April 28, 2026. Earlier roles on record: CFO at Foghorn Therapeutics Inc. (FHTX) until November 14, 2025. Faeth Therapeutics, Inc. reported in an 8-K filed June 15, 2026 that Kristian Humer resigned as Director, effective June 12, 2026. Faeth Therapeutics, Inc. reported in an 8-K filed June 10, 2026 that Kristian Humer was appointed director, effective June 10, 2026. 4D Molecular Therapeutics, Inc. reported in an 8-K filed March 30, 2026 that Kristian Humer was appointed Principal Accounting Officer, effective March 25, 2026. Equibles holds 6 filed executive changes naming Kristian Humer; each is listed under recent activity with its source filing. The proxy statement of Foghorn Therapeutics Inc. reports total compensation of $1,888,603 for Kristian Humer in fiscal 2024, including a base salary of $336,458. Disclosed compensation is on record for 3 fiscal years. Kristian Humer has spoken on 5 earnings calls across 1 company, most recently for Viridian Therapeutics, Inc.\DE on May 9, 2023. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viridian Therapeutics, Inc.\DE includes Scott Myers (CEO and Board Member), Stephen Mahoney (CEO and Board Member), Tomas Kiselak (Chairman) and 7 others.
“effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.”
“Election of two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.”
“I'd like to refer you to our press release issued earlier today for a detailed summary of our financial results for the first quarter 2023 and take this opportunity to review a few items.”
“I'd like to refer you to our press release issued earlier today for a detailed summary of our financial results for the fourth quarter and full year of 2022 and take this opportunity to review a few items.”
“I would like to give a brief summary of the Q2 financials. Cash, cash equivalents, and short-term investments were $161 million as of June 30, 2022, compared with $197 million as of December 31, 2021.”
“I want to open up our comments by stating that we ended the first quarter with $175 million in cash, cash equivalents, and short-term investments as of March 31, 2022.”
“We entered 2022 in a strong financial position. This year, we look to advance multiple programs in thyroid eye disease while expanding our discovery pipeline. We closed out 2021 with approximately $197 million in cash, cash equivalents and short-term investments as of December 31, 2021.”
2026-06-10–present
2026-03-25–present
2021-07-26–present
2021-07-26–present
Start not stated–present
Last confirmed April 28, 2026
2026-06-10–2026-06-12
Start not stated–2023-09-12
Start not stated–2025-11-14
Biotechnology · Healthcare
Chief Accounting Officer
2021-07-26–present
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2026-03-25–present
Biotechnology · Healthcare
Board Member
2026-06-10–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Foghorn Therapeutics Inc. (FHTX) | Chief Financial Officer | $336,458 | $1,888,603 |
| 2022 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial and Business Officer | $561,800 | $2,023,780 |
| 2021 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial and Business Officer | $230,871 | $7,708,958 |
